Disease-X Is A High-Return Business Strategy

 Disease-X is a business strategy, dependent on a series of fallacies, dressed up as an altruistic concern for human welfare. Embraced by powerful people, the world they move in accepts amoral practice in public health as a legitimate path to their version of success. 

In public health, we follow a similarly important business model.

These realities reflect orthodox public health but are poorly compatible with current business models.

The Covid-19 response demonstrated how the sponsors of international public health institutions have found a way to monetize public health.

The public may then regain a degree of freedom if they agree to take a vaccine, which in turn directly benefits the original sponsors of the scheme.

The heavy public investment in Covid-19 mRNA vaccine development enabled pharmaceutical companies and their investors to reap unprecedented returns.

For the public, diversion of resources to fairyland diseases will increase mortality by diverting funding for real threats and productive areas of investment.

If our primary aim is to channel taxpayer funding to development of biotechnologies that the public can then be mandated to buy, to their own detriment but at great benefit to the developers, then Disease-X is the road forward.

https://brownstone.org/articles/disease-x-is-a-high-return-business-strategy/